BTIG raised its price target for Neuronetics (NASDAQ:STIM) to $10 from $6, citing takeaways from recent virtual investor meetings, which focused on how the company’s new CEO, Keith Sullivan, will be reshaping the...
William Blair initiated coverage of Chinook Therapeutics (NASDAQ:KDNY) with an “outperform” rating. The stock closed at $14.60 on Oct. 5. Chinook recently completed a merger with Aduro Biotech to become a leading...
Brookline Capital Markets initiated coverage of Swiss-based Polyphor (SWX:POLN) at a value of 37 CHF a share. The stock was quoted at 6.98 CHF on Oct. 5. Polyphor is a biopharmaceutical company focused on oncology and...
SVB Leerink launched coverage of Immunic (NASDAQ:IMUX) with an “outperform” rating and $45 price target. The stock closed at $18.87 on Oct. 1. Immunic is focused on development of novel therapeutics for the treatment of...
Stifel initiated coverage of Evofem Biosciences (NASDAQ:EVFM) with a “buy” rating and price target of $5. The stock closed at $2.36 on Oct. 1. The company recently launched a vaginal pH-modulator gel, Phexxi, offering a...
H.C. Wainwright launched coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and $24 price target. The stock closed at $6.19 on Sept. 30. Catabasis is developing edasalonexent, an oral small molecule...
William Blair downgraded Selecta Biosciences (NASDAQ:SELB) to “market perform” after the company and partner, Swedish Orphan Biovitrum, announced top-line data from the Phase 2 COMPARE trial, comparing Selecta’s SEL-212...
Alliance Global Partners launched coverage of Trulieve Cannabis (CSE:TRUL) with a “buy” rating and $40 (Canadian) price target. The stock was quoted at $23.74 in afternoon trading on Sept. 25. “We view Trulieve as a...
Alliance Global Partners initiated coverage of Columbia Care (CSE:CCHW) with a “buy” rating and price target of $8 (Canadian). The stock was quoted at $4.41 in afternoon trading on Sept. 25. Columbia Care engages in...
Maxim Group launched coverage of Monopar Therapeutics (NASDAQ:MNPR) with a “buy” rating and a 12-month price target of $11. The stock closed at $4.98 on Sept. 24. Monopar is focused on developing therapies for cancer...